News By Tag
News By Place
FRA Rolls Out 1st Phase of Strategic Refocus With Appointment of Four Bioscience Leaders to Board
The Fitzsimons Redevelopment Authority (FRA) is adding four of the area's most well-known and successful leaders in the Bioscience Industry to its Board of Directors.
Joining the FRA Board are Donald M. Elliman, Jr., Executive Director of the Charles C. Gates Center for Regenerative Medicine and Stem Cell Biology and current Director and former Chair of the Children's Hospital Colorado Board of Directors; William Freytag, PhD, former Chairman and CEO of Myogen, Inc.; James C. T. Linfield, Partner-in-Charge of the Colorado office of Cooley LLP; and David Perez, President and Chief Executive Officer of CaridianBCT, becoming TerumoBCT.
Brown continues, "We're very pleased to welcome our new board members. These leaders are actively involved the bioscience community - locally, nationally and internationally - and maintain those critical relationships with entrepreneurs, companies and research groups required to guide the FRA through its next phase of growth. This is the first time the FRA has had bioscience executives on its board."
Other FRA Board members include: Bruce Benson, President, University of Colorado; Bruce Schroffel, President, University of Colorado Hospital; John Shaw, Principal, McWhinney; Lilly Marks, Vice President for Health Affairs and Executive Vice Chancellor of the Anschutz Medical Campus; Dwight Rider, Principal, Freund Investments;
About Fitzsimons Redevelopment Authority
The FRA directs the commercial developments in the Fitzsimons Life Science District, along with its partner, Forest City Science + Technology Group. Visit: http://www.fitzscience.com.
Vicki Jenings, CPM, Director of Business Relations, Fitzsimons Redevelopment Authority - http://www.fitzscience.com - 720-859-4108 - firstname.lastname@example.org
Maggie Chamberlin Holben, APR, Principal - Absolutely Public Relations - http://www.absolutelypr.com - 303-984-9801 and 303-669-3558 (cell), email@example.com